About selpercatinib
Selective RET kinase inhibitor
Used for
- Treats RET fusion-positive non-small cell lung cancer.
- Treats advanced or metastatic RET-mutant medullary thyroid cancer.
- Treats advanced RET fusion-positive thyroid cancer.
- Treats advanced RET fusion-positive solid tumors in certain circumstances.
Usual adult dose
160 mg by mouth twice daily for adults weighing at least 50 kg; 120 mg twice daily if under 50 kg. Specialist-directed dose adjustments may apply.
Usual dose in children
For patients aged 2 years and older, dosing is based on body surface area and indication; specialist prescribing is required.
Common side effects
- Dry mouth, diarrhea, constipation, or abdominal pain
- High blood pressure
- Fatigue, swelling, or rash
- Raised liver enzymes or low blood cell counts
Important warnings
- Can cause liver injury; liver tests are monitored during treatment.
- May cause high blood pressure, bleeding, or heart rhythm changes.
- Can impair wound healing; treatment may need pausing around surgery.
- Avoid pregnancy; effective contraception is advised during treatment and for one week afterward.
Pregnancy
May harm an unborn baby. Human pregnancy data are limited; avoid use during pregnancy unless clearly necessary.
Breastfeeding
Breastfeeding is not recommended during treatment and for one week after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors can raise selpercatinib levels.
- Strong or moderate CYP3A inducers can lower selpercatinib levels.
- May affect levels of medicines metabolized by CYP2C8 or CYP3A.
- Stomach-acid reducers can lower absorption; timing or treatment changes may be needed.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.